Stockreport

RG6501 (OpRegen®) Phase 1/2a Results Will Be Featured at 2024 Angiogenesis Exudation and Degeneration Meeting in Presentation by Allen Ho, MD, FACS, FASRS [Yahoo! Finance]

Lineage Cell Therapeutics, Inc.  (LCTX) 
PDF company developing allogeneic cell therapies for unmet medical needs, today announced that results showing retinal structure improvements with RG6501( OpRegen ) from a P [Read more]